Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Applied BioCode's Revenue for the
three
months ended in Dec. 2025 was NT$116.5 Mil. Applied BioCode's average Accounts Receivable for the
three
months ended in Dec. 2025 was NT$102.5 Mil.
Hence, Applied BioCode's Receivables Turnover for the
three
months ended in Dec. 2025 was 1.14.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Applied BioCode Receivables Turnover Related Terms
Applied BioCode Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Applied BioCode's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6598 vs ABT, SYK, MDT: Receivables Turnover Comparison
For the Medical Devices subindustry, Applied BioCode's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Applied BioCode Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Applied BioCode's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Applied BioCode's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Applied BioCode (TPE:6598) has a Receivables Turnover of 1.14 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Applied BioCode and its competitors. According to the industry distribution chart, Applied BioCode ranks #370 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 45.6%.
Is Applied BioCode's Receivables Turnover too high?
Applied BioCode's current Receivables Turnover is 1.14. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Applied BioCode's value of 1.14 is 79.3% below this industry median. Based on the distribution chart, Applied BioCode ranks #370 out of 812 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Applied BioCode has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Applied BioCode's Receivables Turnover compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Applied BioCode ranks #370 out of 812 companies for Receivables Turnover. This puts Applied BioCode in the upper half of its industry. The industry median Receivables Turnover is 5.51. Applied BioCode's value of 1.14 is 79.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Applied BioCode's current Receivables Turnover of 1.14 is 79.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Applied BioCode and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Applied BioCode's current Receivables Turnover is 1.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Applied BioCode stock overvalued right now?
Based on GuruFocus' analysis, Applied BioCode (TPE:6598) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$23.34, compared to a current price of NT$27.70 — trading 18.7% above its estimated fair value. The current Receivables Turnover is 1.14 and 79.3% below the Medical Devices & Instruments industry median of 5.51. Applied BioCode's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Applied BioCode (TPE:6598), the current Receivables Turnover is 1.14 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Applied BioCode (TPE:6598) Overvalued in 2026?
Based on GuruFocus' analysis, Applied BioCode stock appears to be overvalued.
The current stock price of NT$27.70 is trading 18.7% above its estimated GF Value™ of NT$23.34.
GuruFocus considers Applied BioCode to be Modestly Overvalued.
Key valuation signals for TPE:6598:
Receivables Turnover: 1.14
GF Value™: NT$23.34 vs. price of NT$27.70 (18.7% above fair value)
Industry Position: 79.3% below the Medical Devices & Instruments median (#370 of 812)
No single metric tells the full story. See the TPE:6598 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Applied BioCode Corp is engaged in designing, developing, manufacturing, and commercializing multiplex testing products for the in-vitro diagnostics market. The company's in-vitro diagnostic products focus on the molecular infectious disease segment of the market with assays that detect pathogens for gastrointestinal tract infections, respiratory infections, and sexually transmitted infections. The firm's products include barcoded magnetic bead technology (BMB). The BMB technology and detection systems assist in the development of multiplexed nucleic acids or protein detection assays. The company also develops applications for other areas of the diagnostics industry including life science research, agricultural testing, and veterinary markets.
74GF Score
Get the complete analysis for TPE:6598
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6598 has been successfully added to your 
